Importantly, targeting this feedback mechanism with clinically used anti-EGFR therapies, including EGFR monoclonal antibodies or kinase inhibitors, significantly increased the therapeutic efficacy of MRTX1133 against KRASG12D-mutated CRC, leading to marked tumor regression and prolonged survival in mice. Here, EGFR is linked to neoplasm.